0
Hepion Pharmaceuticals, Inc. Banner Image

Hepion Pharmaceuticals, Inc. has reached its limit for free report views

Work for Hepion Pharmaceuticals, Inc.? Upgrade Your Profile and unlock all your annual reports.

Hepion Pharmaceuticals, Inc.

  • Ticker HEPA
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Hepion Pharmaceuticals, Inc. Logo Image
  • 11-50 Employees
  • Based in Edison, New Jersey
Hepion Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and other types of hepatitis. The Company's lead drug candidate, CRV431, reduces liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH. Preclinical studies also have demonstratedMore antiviral activities towards HBV, HCV, and HDV through several mechanisms. These diverse therapeutic activities result from CRV431's potent inhibition of cyclophilins, which are involved in many disease processes. Currently in clinical phase development, CRV431 shows potential to play an important role in the overall treatment of liver disease - from triggering events through to end-stage disease.
Hepion Pharmaceuticals, Inc.

Most Recent Annual Report

Hepion Pharmaceuticals, Inc. MOST RECENT 2019 Annual Report and Form 10K

Report Locked. Hepion Pharmaceuticals, Inc. has reached its limit for free report views.